Welcome to our dedicated page for Collplant Biotechnologies news (Ticker: CLGN), a resource for investors and traders seeking the latest updates and insights on Collplant Biotechnologies stock.
CollPlant Biotechnologies Ltd. develops regenerative and aesthetic medicine technologies based on plant-derived recombinant human collagen, or rhCollagen. News about CLGN centers on its BioInk and 3D bioprinting portfolio, including Collink.3D and BioFlex, as well as medical aesthetics programs such as photocurable dermal filler technology and tissue-regeneration applications.
Company updates also cover operating and financial results, distribution expansion for rhCollagen and BioInk products, Vergenix STR commercialization, intellectual-property activity, collaboration developments, capital actions and Nasdaq listing-compliance matters.
CollPlant (NASDAQ: CLGN) announced termination of its development agreement with AbbVie and a companywide cost-reduction plan including ~50% workforce reduction. The company said the actions extend its cash runway into Q4 2026 and it is actively pursuing new strategic partners across aesthetics while advancing three core programs: regenerative fillers, breast implants, and rhCollagen bioinks.
CollPlant also launched the BioFlex DLP bioink kit and expanded North American distribution via a cGMP logistics hub to support clinical supplies and commercial growth.
CollPlant (Nasdaq: CLGN) reported 2025 results: GAAP revenue $2.37M vs $0.52M in 2024, driven by a $2.0M AbbVie milestone. GAAP net loss narrowed to $11.5M ($0.94/sh) from $16.6M. Cash was $5.6M at year-end amid a 25% workforce reduction and cost‑cutting.
Operational highlights include new patents in the U.S., South Korea and Japan, BioFlex launch for DLP bioprinting, expanded North American distribution, and encouraging preclinical data for regenerative breast implants.
CollPlant (Nasdaq: CLGN) received a Nasdaq notice on March 23, 2026, for failing to meet the $1.00 minimum bid under Nasdaq Listing Rule 5550(a)(2). The company has a 180-calendar day cure period until September 21, 2026 to regain compliance by achieving a $1.00 closing bid for 10 consecutive business days.
The company may seek a second 180-day period if it meets market value and other initial listing standards and notifies Nasdaq of intent to cure, potentially via a reverse share split. Ordinary shares remain listed and tradable.
CollPlant (Nasdaq: CLGN) launched a redesigned corporate website on March 18, 2026 to centralize investor, partner, and stakeholder information. The site expands details on the company's rhCollagen technology, product pipeline (breast implants, dermal fillers, bioinks), collaborations, SEC filings, and governance.
The update aims to improve transparency, accessibility, and engagement as CollPlant advances its clinical and preclinical programs and commercialization objectives.
CollPlant Biotechnologies (Nasdaq: CLGN) said it will report full-year 2025 financial results on Thursday, March 26, 2026, before the opening of U.S. financial markets. The announcement sets a date for earnings disclosure and signals when investors can expect results and related company materials.
CollPlant (Nasdaq: CLGN) announced the Korean Patent Office allowed a patent for its photocurable dermal filler covering a polymerizable rhCollagen solution for in situ light-activated tissue augmentation.
The allowance extends protection through 2039, follows a recent Japanese grant, and adds to granted patents in the US, Europe, China, Brazil, Australia, and Israel. According to the company, the global injectable soft-tissue filler market exceeds $6 billion. CollPlant noted a 2021 development and global commercialization agreement with Allergan (AbbVie).
CollPlant (NASDAQ: CLGN) launched BioFlex, a ready-to-print rhCollagen kit for DLP 3D bioprinting, aimed at drug discovery, engineered tissues and organ fabrication.
BioFlex bundles Collink.3D 50 biodegradable polymer with proprietary photoactive agents and formulation guidelines to enable tunable, high-resolution, reproducible bioinks and faster development.
CollPlant (NASDAQ: CLGN) announced Feb 17, 2026 strategic positioning of a photocurable rhCollagen dermal filler to address facial volume loss linked to rapid weight loss, including patients on GLP-1 therapies. The platform is preclinical and aims to restore structure, integrate with tissue, and potentially improve skin quality over time.
The company is evaluating clinical and commercial pathways to address a growing aesthetic need driven by expanding GLP-1 use.
CollPlant (NASDAQ: CLGN) entered a definitive agreement for a registered direct offering of 1,600,000 ordinary shares at $1.25 per share for gross proceeds of approximately $2.0 million. Concurrently, unregistered Series A and B warrants to purchase up to 1,600,000 shares each will be issued.
The Series A warrants have a $1.25 exercise price and expire five years after the effective registration date; Series B warrants have a $1.25 exercise price and expire 18 months after that date. The offering is expected to close on or about February 6, 2026, with H.C. Wainwright as placement agent.
CollPlant Biotechnologies (Nasdaq: CLGN) reported third-quarter 2025 results and a corporate update on Nov 26, 2025. Key commercial moves include a new U.S. logistics center becoming operational this quarter and appointment of a North America commercial head to expand rhCollagen and BioInk distribution.
Financial highlights: Q3 GAAP revenue $77k (vs $4k year-ago); 9M revenue $2.3M driven by a $2.0M AbbVie milestone; cash $8.5M as of Sept 30, 2025; GAAP 9M net loss narrowed to $8.3M from $12.7M. Company initiated a ~25% workforce reduction and cost-prioritization to extend runway.